文献速递衰弱、肌少症与跌倒老年慢病共病管理

卡格列净在衰弱状态下的疗效与安全性:CANVAS与CREDENCE试验分析

The Efficacy and Safety of Canagliflozin by Frailty Status in Participants of the CANVAS and CREDENCE Trials.
PubMed 文献 · J Am Geriatr Soc · 2025-03-19

该研究为CANVAS项目与CREDENCE试验的事后汇总参与者水平数据分析,共纳入14543例2型糖尿病患者,按衰弱指数(FI>0.25)定义衰弱,56%存在衰弱。卡格列净在衰弱与非衰弱亚组中均改善心血管与死亡终点,安全性相似,仅渗透性利尿的交互作用显著。

要点

  • 衰弱者占56%,卡格列净降低MACE(HR 0.80)与全因死亡(HR 0.81)。
  • 衰弱与非衰弱亚组疗效交互作用均不显著,安全性总体相似。
  • 渗透性利尿在非衰弱者风险更高(HR 3.05 vs 1.67),交互作用显著。

核心结论

  • 卡格列净在衰弱与非衰弱2型糖尿病患者中均改善心血管与死亡终点,安全性特征相似。

研究设计与样本

  • CANVAS项目(CANVAS与CANVAS-R)和CREDENCE试验的事后汇总、参与者水平数据分析,共14543例参与者。

主要发现

  • 衰弱者占56%,平均年龄63.2岁,女性占35.3%。
  • 衰弱亚组MACE的HR为0.80(95%CI 0.70-0.90),非衰弱亚组为0.91(95%CI 0.75-1.09),交互作用P=0.27。
  • 衰弱亚组心血管死亡HR为0.79(95%CI 0.67-0.95),非衰弱亚组为0.94(95%CI 0.70-1.27),交互作用P=0.38。
  • 衰弱亚组全因死亡HR为0.81(95%CI 0.70-0.94),非衰弱亚组为0.93(95%CI 0.74-1.16),交互作用P=0.39。
  • 渗透性利尿在衰弱亚组HR为1.67(95%CI 1.22-2.28),非衰弱亚组HR为3.05(95%CI 2.13-4.35),交互作用P=0.01。

关键数值与推荐

  • 衰弱定义采用基于缺陷累积方法的衰弱指数(FI),FI>0.25判定为衰弱。

临床怎么用

  • 对衰弱2型糖尿病患者可考虑启用SGLT2抑制剂卡格列净,以改善心血管与死亡结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to improve renal and cardiovascular outcomes in patients with type 2 diabetes. Limited evidence exists about the efficacy and safety of SGLT2 inhibitors in patients with frailty. METHODS: This was a post hoc pooled, participant-level data analysis of the CANVAS Program (CANVAS and CANVAS-R) and the CREDENCE trial. We examined the effect of canagliflozin on: (1) Major adverse cardiovascular events (MACE), (2) Cardiovascular mortality, (3) all-cause mortality, and (4) key safety outcomes. Frailty was defined by a Frailty Index (FI) based on a deficit accumulation approach (FI > 0.25: frail). Cox proportional-hazard models were used to estimate the efficacy and safety of canagliflozin overall and according to frailty status. RESULTS: There were 14,543 participants (10,142 from the CANVAS Program, 4401 from the CREDENCE trial). Their mean age was 63.2 years; 35.3% were female. Frailty was present in 56% of the study participants. The benefits of canagliflozin were observed in both the frail and non-frail subgroups: HRs for MACE 0.80 (95% CI 0.70-0.90) in the frail versus 0.91 (95% CI 0.75-1.09) in the non-frail (p for interaction = 0.27); HRs for cardiovascular mortality 0.79 (95% CI 0.67-0.95) in the frail versus 0.94 (95% CI 0.70-1.27) in the non-frail (p for interaction = 0.38); HRs for all-cause mortality 0.81 (95% CI 0.70-0.94) in the frail versus 0.93 (95% CI 0.74-1.16) in the non-frail (p for interaction = 0.39). Adverse events were similar among frail and non-frail participants, except for osmotic diuresis (HRs 1.67, 95% CI 1.22-2.28 in the frail vs. 3.05, 95% CI 2.13-4.35 in the non-frail, p for interaction = 0.01). CONCLUSIONS: Canagliflozin improved cardiovascular and mortality endpoints in participants with type 2 diabetes irrespective of frailty status, with a similar safety profile. Our findings, in addition to those from other recent studies, provide evidence to support the introduction of SGLT2 inhibitor therapy in patients perceived to be frail. TRIAL REGISTRATION: ClinicalTrials.gov CANVAS: NCT01032629; CANVAS-R: NCT01989754; CREDENCE: NCT02065791.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Nguyen TN, Yu J, Perkovic V, et al. The Efficacy and Safety of Canagliflozin by Frailty Status in Participants of the CANVAS and CREDENCE Trials. J Am Geriatr Soc. 2025. PMID: 40105285. doi:10.1111/jgs.19444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。